





# Metastatic Diseases:

Past, Present and Future in Oncology March 18-19th 2016

# 7th Serbian-French Oncology Congress

March 18-19th2016



Topic: Metastatic Diseases: Past, Present and Future in Oncology Rectorate hall, University of Novi Sad, SERBIA

 Dear colleagues and friends, We are honored to announce 7th Serbian-French Oncology Congress. This traditional meeting is one of the biggest regional meetings with international participation and is covering all the novelties in the diagnostics and treatment of malignant diseases, as well as economic aspects of cancer management in Serbia..

On behalf of the Organizing Committee,

- Prof dr Jean-Piere Lotz president
- Prof dr Yazid Belkacemi
- Prof dr Darjana Jovanović
- Prof dr Dušan Jovanović
- Assistant prof Lazar Popović

# Registration fee is 50 € and includes:

- Attendance to all scientific sessions;
- Admission to the exhibition;
- Coffee breaks and lunch breaks,
- Delegate pack (congress badge, congress bag, all congress materials),
- Certificate of attendance

Please, mark your calendars and join us in beautiful Novi Sad by registering for 7th Serbian – French Oncology Congress. Welcome!











Metastatic Diseases: Past, Present and Future in Oncology

#### Friday 18, March 2016

08.00-09.00 Registration 09.00-09.20 Opening Remarks

#### SESSION I

09.20-09.30 World Statistics Since 1950 Jean-Pierre Lotz(Paris, France)

09.30-09.40 Cancer Epidemiology in Vojvodina

Dušan Jovanović (Sr. Kamenica, Serbia)

09.40-10.00 Biology: It's Role in Therapeutic Decisions.
Micro-RNA, Exosomes Chantal Tsé (Paris, France)

10.00-10.20 Darwin Concept / Selection and Pressure Daniélé Grazziotin-Soares (Paris, France)

10.20-10.30 Discussion

10.30-11.00 Coffee Break

#### SESSION II

11.00-11.20 Tumor Growth: the Mathematical Point of View Jean Clairambault (Paris, France)

11.20-11.40 Bio-similar and Generic Drugs Isabelle Debrix (Paris, France)

11.40-12.00 Chinese Alternative Medicine in Oncology Li Sen (Shenyang, China)

12.00-12.15 Discussion

12.15-13.15 Satellite Symposium ROCHE

13.15-14.15 Lunch Break

#### SESSION III

14.15-14.35 Do we Have to Treat Different Metastatic Diseases? Vladimir Kovčin (Belgrade, Serbia)

14.35-15.00 Objectives & Goals: the Graal of 'the p Value' Versus QOL. DUEL: Pro p-value: Lazar Popović (Sr. Kamenica, Serbia) Pro-QOL: Jean-Pierre Lotz (Paris, France)

15.00-15.30 Immunotherapy in Solid Tumors Yosef Yarden (Rehovot, Israel)

15.30-15.45 Discussion

### 16.15-17.00 Satellite Symposium MERCK

#### SESSION IV

17.00-17.30 Use of PET/CT in Metastatic Disease: Therapeutic impact? Silvija Lučić (Sr. Kamenica, Serbia)

17.00-17.45 Geriatric Oncology: a New Discipline? Djamel Ghebriou (Paris, France)

# 17.45-18.30 Satellite Symposium NOVARTIS

#### Saturday March 19,

• 09.00-11.00 AROME Sessions

"Controversies in Multidisciplinary Breast Cancer Management" Imaging- Magnetic Resonance Imaging of the Breast is Mandatory as Routine Use in 2016. Con: Dragana Djilas (Sr. Kamenica, Serbia) Pro: Dragana Bogdanovic (Sr. Kamenica, Serbia)

Surgery- Axillary lymph Node Dissection is still a Standard of Care in Macrometastatic Sentinel Node Biopsy Con: Marie Pierre Chauvet (Lille, France); Pro: Vicko Ferenc (Sr. Kamenica, Serbia)

Radiotherapy- Regional Nodal Irradiation is the Standard of Care for all Node Positive Patients Con: Abraham Kuten (Haifa, Israel) Pro: Yazid Belkacemi (Paris, France)

Endocrine therapy- Aromatase Inhibitors Should be Indicated in all Postmenopausal Patients with Hormone Receptor Positive Breast Cancer Pro: Ivana Bozovic Spasojevic (Belgrade, Serbia) Con: Snezana Susnjar (Belgrade, Serbia)

# 11.00-11.45 Satellite Symposium TAKEDA

#### 11.45-12.00 Coffee Break

12.00-13.00 ASPEN Provided Symposium: Thrombo-Embolism in Cancer Patients Darjana Jovanovic (Sr. Kamenica, Serbia), Alex Spyropoulos (Rochester, NY, USA), Grigoris Gerotziafas (Paris, France), Franco Piovella (Pavia, Italy)

#### 13.00-13.45 Buffet Lunch Break

# 13.45-14.30 Satellite Symposium ASTRA ZENECA

# ● 14.30-16.00 Student and Young Doctors Session:

- Preservation of Fertility
- Long-lasting Grade I and II Toxicities: Incidence on QOL
- Continuous Versus Intermittent Therapy in Metastatic Disease
- Bone Preservation
- Prevention of Thrombo-embolism Events
- Morphinic Support in Metastatic Diseases







